According to the World Health Organization classification of tumours of the haematopoietic system and lymphoid tissue, common clinical malignant blood diseases include acute myeloid leukaemia, malignant lymphoma, myeloproliferative neoplasms (including chronic myeloid leukaemia), myelodysplastic syndromes, etc. Most malignant blood diseases have severe symptoms, are difficult to treat, expensive to treat, have poor efficacy, are also prone to relapse, have a poor prognosis, and are very likely to undermine the confidence of patients and their families.